Maribeth C Lovegrove1, Deborah Dowell1, Andrew I Geller1, Sandra K Goring1, Kathleen O Rose1, Nina J Weidle1, Daniel S Budnitz1. 1. Maribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Abstract
OBJECTIVES: To estimate the number of US emergency department visits for prescription opioid harms by patient characteristics, intent, clinical manifestations, and active ingredient. METHODS: We used data from medical record-based surveillance from a nationally representative 60-hospital sample. RESULTS: Based on 7769 cases, there were 267 020 estimated emergency department visits annually (95% confidence interval [CI] = 209 833, 324 206) for prescription opioid harms from 2016 to 2017. Nearly half of visits (47.6%; 95% CI = 40.8%, 54.4%) were attributable to nonmedical opioid use, 38.9% (95% CI = 32.9%, 44.8%) to therapeutic use, and 13.5% (95% CI = 11.0%, 16.0%) to self-harm. Co-implication with other pharmaceuticals and concurrent illicit drug and alcohol use were common; prescription opioids alone were implicated in 31.5% (95% CI = 27.2%, 35.8%) of nonmedical use visits and 19.7% (95% CI = 15.7%, 23.7%) of self-harm visits. Unresponsiveness or cardiorespiratory failure (30.0%) and altered mental status (35.7%) were common in nonmedical use visits. Gastrointestinal effects (30.4%) were common in therapeutic use visits. Oxycodone was implicated in more than one third of visits across intents. CONCLUSIONS: Morbidity data can help target interventions, such as dispensing naloxone to family and friends of those with serious overdose, and screening and treatment of substance use disorder when opioids are prescribed long-term.
OBJECTIVES: To estimate the number of US emergency department visits for prescription opioid harms by patient characteristics, intent, clinical manifestations, and active ingredient. METHODS: We used data from medical record-based surveillance from a nationally representative 60-hospital sample. RESULTS: Based on 7769 cases, there were 267 020 estimated emergency department visits annually (95% confidence interval [CI] = 209 833, 324 206) for prescription opioid harms from 2016 to 2017. Nearly half of visits (47.6%; 95% CI = 40.8%, 54.4%) were attributable to nonmedical opioid use, 38.9% (95% CI = 32.9%, 44.8%) to therapeutic use, and 13.5% (95% CI = 11.0%, 16.0%) to self-harm. Co-implication with other pharmaceuticals and concurrent illicit drug and alcohol use were common; prescription opioids alone were implicated in 31.5% (95% CI = 27.2%, 35.8%) of nonmedical use visits and 19.7% (95% CI = 15.7%, 23.7%) of self-harm visits. Unresponsiveness or cardiorespiratory failure (30.0%) and altered mental status (35.7%) were common in nonmedical use visits. Gastrointestinal effects (30.4%) were common in therapeutic use visits. Oxycodone was implicated in more than one third of visits across intents. CONCLUSIONS: Morbidity data can help target interventions, such as dispensing naloxone to family and friends of those with serious overdose, and screening and treatment of substance use disorder when opioids are prescribed long-term.
Authors: Kristin Dwyer; Alexander Y Walley; Breanne K Langlois; Patricia M Mitchell; Kerrie P Nelson; John Cromwell; Edward Bernstein Journal: West J Emerg Med Date: 2015-04-01
Authors: Derrick C Gibson; Mukaila A Raji; Holly M Holmes; Jacques G Baillargeon; Yong-Fang Kuo Journal: Mayo Clin Proc Date: 2022-02-05 Impact factor: 7.616
Authors: Daniel S Budnitz; Nadine Shehab; Maribeth C Lovegrove; Andrew I Geller; Jennifer N Lind; Daniel A Pollock Journal: JAMA Date: 2021-10-05 Impact factor: 56.272
Authors: Salva N Balbale; Lishan Cao; Itishree Trivedi; Jonah J Stulberg; Katie J Suda; Walid F Gellad; Charlesnika T Evans; Neil Jordan; Laurie A Keefer; Bruce L Lambert Journal: Am J Health Syst Pharm Date: 2022-01-05 Impact factor: 2.980
Authors: Tetyana Kendzerska; Tara Gomes; Atul Malhotra; Andrea S Gershon; Marcus Povitz; Daniel I McIsaac; Shawn D Aaron; Frances Chung; Gregory L Bryson; Robert Talarico; Tahmid Ahmed; Michael Godbout; Peter Tanuseputro Journal: PLoS One Date: 2022-06-28 Impact factor: 3.752
Authors: Isaac See; Runa H Gokhale; Andrew Geller; Maribeth Lovegrove; Asher Schranz; Aaron Fleischauer; Natalie McCarthy; James Baggs; Anthony Fiore Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Shabbar I Ranapurwala; Christopher L Ringwalt; Brian W Pence; Sharon Schiro; Naoko Fulcher; Agnieszka McCort; Bethany L DiPrete; Stephen W Marshall Journal: Am J Prev Med Date: 2020-12-10 Impact factor: 5.043
Authors: Molly M Jeffery; Nancy E Morden; Marc Larochelle; Nilay D Shah; W Michael Hooten; Ellen Meara Journal: Med Care Date: 2020-01 Impact factor: 3.178
Authors: Sukarma Tanwar; Andrew I Geller; Maribeth C Lovegrove; Daniel S Budnitz Journal: MMWR Morb Mortal Wkly Rep Date: 2020-08-14 Impact factor: 17.586